[Subcutaneous histamine in migraine prevention]
Brito V, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A, Glujovsky D, López A, Rey-Ares L
Record ID 32015000865
Spanish
Authors' recommendations:
Low-quality evidence did not show the superiority of subcutaneous histamine administration in migraine prevention when compared with conventional strategies such as propanolol, topiramate, valproate an botulinum toxin. In a single study including 30 patients, the superiority of histamine was observed when compared to placebo, but these results were not replicated in later studies. Based on these findings, the identified coverage policies do not cover the use of histamine in migraine prevention, considering its administration experimental until further evidence is available.
Details
Project Status:
Completed
Year Published:
2015
URL for published report:
www.iecs.org.ar/home-ets/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
MeSH Terms
- Humans
- Migraine Disorders
- Histamine
- Injections, Subcutaneous
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.